Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab plus topical corticosteroids in children 6–11 years with severe atopic dermatitis
2016-004997-16Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2016-004997-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004997-16.